Science 37 has created a new clinical trial operating model – the metasite™ – that unlocks access so researchers can find the right patients, and patients can find the right trials. Its Network Oriented Research Assistant, NORA™, is an accelerated patient-centric mobile research platform that connects everyone safely and securely. Science 37 offers end-to-end clinical trial services without geographic limitations, making clinical research faster to accelerate biomedical discovery. Ultimately, Science 37 enables better, faster, people-powered science and brings clinical trials to scale.
"It's clear SGBV shares our mission of unlocking access to clinical trials and how that fits into the larger digital revolution that uses technology to enable patients to take a more proactive role in their own health. We all share the common goal of bringing new cures to people faster. By working closely with Sanofi, Science 37 will exponentially accelerate clinical research in neurodegenerative diseases and other rare genetic disorders."
co-founder and CEO, Science37
ImmuneXcite is developing transformative immuno-oncology products that utilize the power of both the innate and adaptive immune response. The company is using its mAbXcite technology to leverage the innate immune system to initiate an anti-tumor response, which subsequently primes the natural adaptive immune response to further limit tumor growth and metastasis.
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Formed in 2014 by renowned biotech industry leader, Tony Coles, M.D., and protein folding science pioneer, Susan Lindquist, Ph.D., the company is initially focused on discovering disease-modifying therapies for patients with Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Leveraging its three integrated platforms, Yumanity’s innovative new approach to drug discovery and development concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding.
"Sanofi-Genzyme BioVentures shares Yumanity's vision of following the science where it leads, and we are thrilled to work together in our efforts to bring much needed new therapies to patients living with Alzheimer’s, Parkinson’s and Lou Gehrig’s Diseases, among other debilitating and life threatening neurodegenerative diseases."
Tony Coles, M.D.
Chairman and CEO, Yumanity
NeuroVia, Inc. is a specialty pharmaceutical company focused on the development of therapeutics to treat orphan disease with significant unmet medical need.
Selecta is developing immune modulating nanomedicines that enable novel biologic therapies by preventing harmful immune responses. Proprietary Synthetic Vaccine Particles (SVP) elicit lasting and antigen-specific tolerance to co-formulated biologic drugs. Selecta is conducting clinical studies to develop the first non-immunogenic biologic therapy to treat severe gout and is focused in the near-term on developing immunotherapeutic candidates that eliminate immune responses to adeno-associated virus (AAV) vectors that would enable a wide range of new applications for gene therapies.
"Sanofi has been a pioneer in recognizing the importance of antigen-specific immune modulation in vaccines, allergies, enzyme replacement therapy and auto-immune diseases. SGBV is of tremendous help to facilitate our dialogue within Sanofi and an esteemed member of our investor network."
Werner Cautreels, President & CEO, Selecta Biosciences
Ovid Therapeutics Inc. is a privately-held, New York based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development.
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body's own immune system to fight cancer. Unum's lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is in clinical testing to assess safety and efficacy.
"It's wonderful to have SGBV as a key part of the series A financing for Unum. Bernard and his team have established a strong track record of building great companies with the potential to really change the practice of medicine. Their strategic focus and knowledge of what Pharma values will be valuable assets for Unum"
President & CEO, Unum Therapeutics
Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.
Immune Design is a public immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™. Immune Design has offices in Seattle, Washington and South San Francisco, California.
"We are very pleased that SGBV has decided to invest in Immune Design. Our companies share the vision of harnessing the immune system to discover and develop new immune-based therapies in a number of large human diseases in which both companies are interested."
President & CEO, Immune Design
Common Sensing is introducing GoCap, a safer and more convenient way for diabetics to track and dose insulin. GoCap empowers patients by reducing the burden of manual logging, while providing helpful safety alerts and reminders. The aim is to connect patients, family, and care providers with better information feedback. By improving care engagement and motivation, GoCap holds the potential to improve quality of life for diabetics and reduce cost burdens for the health care system.
"Sanofi-Genzyme BioVentures is not hesitant to reach out into its network to provide hands-on mentorship and development support resources that are invaluable to any early-stage startup."
CEO & Co-Founder, Common Sensing
Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). EDI200 is a recombinant version of ectodysplasin A1 – the molecule that is missing in patients with XLHED. XLHED is a rare orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations.
Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisors. The company is based in Cambridge, Massachusetts.
"We are excited about working closely with Sanofi-Genzyme BioVentures as we move our lead product, EDI200, through clinical development. Clearly, their expertise in creating value in the rare disease space is unparalleled in the biopharmaceutical industry and we look forward to leveraging this know-how."
President & CEO, Edimer Pharmaceuticals
Ultragenyx is a public, clinical-stage biotechnology company committed to bringing to market life-transforming therapeutics for patients with rare and ultra-rare metabolic genetic diseases. Founded in 2010, the company is rapidly building a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no effective treatments.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
Kahr is a privately held, clinical stage company pioneering the development of multi-functional fusion-protein drugs with potential applications in oncology and autoimmune diseases.
"Our partnership with SGBV has been exceptionally productive in ways that exceeds funding per se, especially the valuable development guidance we have obtained from Sanofi R&D."
CEO, Kahr Medical
Esperance Pharmaceuticals, Inc. is a clinical stage company developing a new class of targeted anticancer drugs using its novel Cationic Lytic Peptide (CLYP™) platform technology.
The Company’s drug candidates, called targeted membrane‐disrupting peptides (tMDPs) and antibody drug conjugates (ADCs) selectively seek and destroy cancer cells, including cells known to be resistant to chemotherapeutic drugs, without harming normal cells. EP-100, the Company's lead candidate recently completed a Phase 2 study for the treatment of advanced refractory/recurrent ovarian cancer.
Founding investors include the Louisiana Fund I, Themelios Ventures and Research Corporation Technologies. Additional investors include Sanofi-Genzyme BioVentures, Advantage Capital Partners, Louisiana Technology Fund and Private Investors.
"We are pleased to have Sanofi-Genzyme BioVentures as an investor in Esperance. Esperance values Sanofi’s record of innovation and global experience in developing cancer drugs."
President & CEO, Esperance Pharmaceuticals
bluebird bio is a public company developing innovative gene therapies for severe genetic and orphan diseases. At the heart of bluebird bio's product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company's novel approach uses stem cells harvested from the patient's bone marrow into which a healthy version of the disease causing gene is inserted. After being grown in culture, those cells are given back to the patient. bluebird bio's approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy. bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell anemia. The company is also applying its gene therapy platform to oncology through the development of chimeric antigen receptor T-cells in collaboration with Baylor University and Celgene.
GlycoMimetics is a public, clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Our lead program recently completed a Phase 2 clinical trial in vaso-occlusive crisis of sickle cell disease.
"GlycoMimetics has enjoyed a very positive and productive relationship with Sanofi-Genzyme BioVentures. We have appreciated the opportunity to consult with functional area experts as well as to be in regular communication about the progress of our unpartnered programs. It’s great to have a chance to be ‘on the radar screen'."
Rachel K. King
Uniquely positioned at the intersection of stem cell science and orphan disease, Fate Therapeutics is pioneering the discovery and development of innovative adult stem cell modulator therapeutics with the potential to cure or transform the lives of patients with rare life-threatening disorders. The Company’s lead program, ProHema, an innovative cordblood-derived cell therapy containing ex vivo pharmacologically-modulated hematopoietic stem cells (HSCs), is currently in Phase 2 testing in patients with leukemia undergoing hematopoietic transplantation. The Company plans to pursue clinical evaluation of pharmacologically modulated HSCs in patients with rare genetic disorders, an area of tremendous unmet medical need in which the curative potential of cord blood transplantation is well recognized. In addition, Fate Therapeutics is developing proprietary WNT7a-based protein therapeutics that have shown efficacy in preclinical models of muscular dystrophy. To advance its discovery efforts, the Company applies its award-winning, proprietary, induced pluripotent stem cell (iPSC) technology to generate rare cell populations and model disease. Fate Therapeutics is a public company headquartered in San Diego, CA, with a subsidiary in Ottawa, Canada.
KaloBios is a public biopharmaceutical company focused on the development of monoclonal antibody therapeutics to treat serious medical conditions with a primary clinical focus on severe respiratory diseases and cancer. Using its proprietary Humaneered® antibody technology, KaloBios has produced a portfolio of patient targeted, first-in-class, antibodies. The company has three monoclonal antibodies at the clinical development stage, including KB001-A (a Humaneered®, anti-PcrV of Pseudomonas aeruginosa (Pa) antibody fragment (Fab’)), which Sanofi licensed from KaloBios. KB001-A is in clinical development for the prevention and treatment of infections caused by Pa, a gram-negative bacterium in individuals with cystic fibrosis (CF) and pneumonia in mechanically ventilated patients (Pa VAP).
Proteostasis Therapeutics, Inc. (PTI) is developing disease-modifying therapeutics for diseases of protein processing. Using the DRT™ platform, a phenotypic screening approach based on the use of functionally pertinent cellular assays and disease relevant models, PTI identifies highly selective drug candidates that modulate the proteostasis imbalance in the cell. PTI's lead program is focused on treating cystic fibrosis.
Valerion Therapeutics is an emerging science-driven company focused on the development of biotherapeutics for orphan genetic diseases. Valerion generates unique product candidates utilizing a proprietary delivery technology platform that takes advantage of tissue targeting via a novel antibody (3E10) with cell-penetrating properties dependent on a tissue-localized membrane transporter (ENT2). Because the ENT2 transporter is naturally enriched in critical organs (ex. skeletal muscle), Valerion is able to construct targeted products; thereby providing a novel way to treat a number of diseases with limited or no current therapeutic options.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
Lumena Pharmaceuticals, acquired by Shire plc in June 2014, is a biopharmaceutical company dedicated to providing better treatment options for adults and children who suffer from rare and debilitating liver diseases and serious metabolic disorders. The company is focused on developing oral therapeutics to improve liver function, relieve disease symptoms and dramatically benefit patient health.